Principle
NF-κB is a critical regulator of inflammatory responses, proliferation and differentiation of T-cells. The aberrant activation of NFkB can contribute to the development of autoimmunity, chronic inflammation, or lymphoid cancer. Jurkat cells are human T lymphocyte cells widely used to study T cell signaling. Signosis developed a stable Jurkat NFkB-luciferase reporter stable cell line, which can be used for easily monitoring the activation of NFkB activation in T cells through sensitive luciferase analysis. This cell line was established by transfection using a pTA-NFkB-luciferase reporter vector, along with hygromycin expression vector followed by hygromycin selection. The hygromycin resistant clones were subsequently screened for luciferase activity induced by TNFapha treatment.
Inflammation/NFKB
Introduction
The NF-κB signaling pathway is a key regulator of inflammation, immune response, and cell survival, controlling the transcription of pro-inflammatory cytokines and stress-response genes. Aberrant NF-κB activation is strongly associated with chronic inflammation, autoimmune diseases, cancer, and neurodegenerative disorders, making it a high-value target in inflammation research and therapeutic development.
Our NF-κB luciferase reporter assays and NF-κB reporter stable cell lines provide a high-sensitivity NF-κB assay for quantitative measurement of pathway activation. These luciferase reporter systems enable reliable detection of NF-κB activity induced by inflammatory cytokines, GPCR signaling, Toll-like receptor agonists, and small-molecule compounds.
Designed for inflammation-focused drug screening, these NF-κB assays deliver high signal-to-background ratios, excellent reproducibility, and compatibility with high-throughput screening (HTS). They are ideally suited for mechanistic studies, compound profiling, and inhibitor discovery in academic research and pharmaceutical drug discovery programs.
